|
Type of Company:
Type:
|
Company
|
Ownership: |
Publicly Traded |
Company Size: |
20 Employees In BC (20 Total)
20 In BC (20 Total)
|
Year Founded: |
1967 |
Sector: |
Biotech/Life Sciences
Biotech/Life Sciences
|
Region: |
Lower Mainland / South Coast
Lower Mainland
|
Tags: |
replicel, biotech, hair, hair loss, implantation
|
Profile Views: |
1,303 Company Profile Views |
|
|
RepliCel Life Sciences Inc. is developing a scientific technology that has the potential to become the world's first, minimally invasive, permanent solution for hair loss in men and women.
Using autologous cell implantation technology, dermal sheath cup cells are taken from a patient's own healthy hair follicles and are replicated into the millions over a three month period. These cells are reintroduced into areas of hair loss and the anticipated result is the development of new hair follicles. The procedure has been in development over the past nine years by the company's research scientists and medical experts, and is currently undergoing phase I/IIa clinical trials in Europe.
|
|
|
Date |
Type |
Amount |
Investors |
Dec 22, 2021 |
Private Placement |
$1 Million CAD |
Final tranche of the investment by MainPointe Pharmaceuticals as outlined in the share purchase agreement signed by the parties. The final tranche involved the issuance of 1,479,882 common shares by RepliCel in exchange for CAD$998,921 which has now been received by the Company. |
Feb 22, 2021 |
Private Placement |
$2.7 Million CAD |
|
Nov 15, 2020 |
Unattributed |
$2.7 Million CAD |
|
Date |
Type |
Amount |
Investors |
Dec 22, 2021 |
Private Placement |
$1M CAD |
Final tranche of the investment by MainPointe Pharmaceuticals as outlined in the share purchase agreement signed by the parties. The final tranche involved the issuance of 1,479,882 common shares by RepliCel in exchange for CAD$998,921 which has now been received by the Company. |
Feb 22, 2021 |
Private Placement |
$2.7M CAD |
|
Nov 15, 2020 |
Unattributed |
$2.7M CAD |
|
|
|
Want More RepliCel Life Sciences Inc. News? 1 2 3
|
Next »
|
|
|
|
|
Jan 17, 2022
|
RepliCel Announces Material Patent Milestones
|
Jan 4, 2022
|
RepliCel Closes $1 Million Final Tranche of Strategic Investment Commitment and Terminates License Agreement with Shiseido
|
Nov 15, 2021
|
RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line
|
Nov 9, 2021
|
RepliCel Announces Dermal Injector Update
|
Nov 8, 2021
|
RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell T
|
Jul 14, 2021
|
RepliCel Applies for Manufacturing Approval for Its Collagen and Tissue Regeneration Cell Therapies
|
Jun 14, 2021
|
Vancouver-based Cell Therapy Company RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor
|
Jun 2, 2021
|
Vancouver-based RepliCel Launches Testing of Dermal Injector Units
|
May 28, 2021
|
RepliCel Launches Preparations for Second Skin Rejuvenation and Tendon Regeneration Clinical Studies
|
May 21, 2021
|
RepliCel Launches the Next Stage of a Research Project with the University of British Columbia to Build World-Class Hair Follicle Cell Data Map
|
|
1 - 10 of 42 results
|
|
 |
|
|
|
Share This Company Profile |
|
Disclaimer: Company Profiles in the Tech Directory on T-Net are created, edited and maintained primarily by employees within individual companies, and are subject to continual change without notice and possible errors and/or omissions. Information within the pages of this Tech Directory is of a general nature intended only for informational purposes, and such information should not be relied upon. T-Net does not warrant or guarantee the quality, accuracy or completeness of such information and expressly disclaims liability for any loss, inconvenience or damages (including special, indirect or consequential damages) caused as a result of any errors in, or omissions from, such information. If you see an error, please let us know. Copyright T-Net. All rights reserved.
|
|